These observations are in agreement with those reported by Franco et al, who also found that CDK4/6 inhibition leads to an enhanced activation of the mTOR pathway and consequent sensitivity of pancreatic cancer cells to mTOR inhibitors (Franco et al, 2016). This evidence concerns the gene MTOR and pancreatic neoplasm.